This peer-reviewed article, published in Vaccine, evaluates the potential cost-effectiveness of alternative strategies for introducing a hypothetical schistosomiasis vaccine in Madagascar and Burkina Faso. The study uses a Markov model to estimate health and economic outcomes under different vaccination strategies and hypothetical vaccine profiles, drawing on country-specific cost-of-illness and health-related quality-of-life data.
Key findings and insights
How can the findings be used?
These findings can inform early-stage value assessments and target-population design for schistosomiasis vaccine candidates still under development. Since cost-effectiveness depended strongly on including adults rather than restricting vaccination to school-aged children, this may be a relevant consideration for future country-level policy discussions once a licensed vaccine becomes available.
Thumbnail image credit: GAVI
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.